Diaccurate Appoints Scott Filosi as CEO Our Oral Optimized S6 Kinase Inhibitor Is Now Rupitasertib Our Selective KIF20A Inhibitor is now EVX-020 Latest news Diaccurate Announces the Appointment of Scott Filosi as CEO and Corporate Name Change to Evexta Bio November 6, 2023 Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023 April 6, 2023 Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs) January 5, 2023 Upcoming events JP Morgan Annual Healthcare Conference 2024 January 8, 2024 - January 11, 2024 ASCO Annual Meeting 2024 May 31, 2024 - June 4, 2024
Diaccurate Announces the Appointment of Scott Filosi as CEO and Corporate Name Change to Evexta Bio November 6, 2023
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023 April 6, 2023
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs) January 5, 2023
